{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-012840","form_type":"8-K","ticker":"NOTV","cik":"0000720154","company_name":"Inotiv, Inc.","filed_at":"2021-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.605259+00:00","generated_at":"2026-06-29T01:07:56.041973+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inotiv provides Q1 2021 financials for Bolder BioPATH & HistoTox; CCO Flynn departs with severance","bullets":["Bolder BioPATH Q1 2021 net income $868K, revenue $3.74M; acquired for $18.5M cash, $1.5M notes, $34.5M in shares in May 2021.","HistoTox Labs Q1 2021 net income $962K, revenue $2.62M; acquired for $22.3M cash in April 2021.","Former CCO Joseph Flynn terminated Sep 8; severance includes 4-month salary continuation, COBRA reimbursement.","Flynn forfeits unvested options/RSUs, can exercise 7,000 options until Oct 8, 2021.","Non-solicitation obligation reduced from 24 to 6 months; mutual non-disparagement and release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-012840","json":"https://secwatch.observer/filing/0001558370-21-012840.json","markdown":"https://secwatch.observer/filing/0001558370-21-012840.md","text":"https://secwatch.observer/filing/0001558370-21-012840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/720154/000155837021012840/0001558370-21-012840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/720154/000155837021012840/notv-20210927x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:07:56.041973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7cb7d30bdf","claim":"Joseph E. Flynn was terminated as Chief Commercial Officer at Inotiv, Inc..","evidence_excerpt":"Inotiv, Inc. (the “Company”) and Joseph E. Flynn, the Company’s former Chief Commercial Officer, entered into an agreement (the “Separation and Release Agreement”) in connection with the termination of Mr. Flynn’s employment on September 8, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/720154/000155837021012840/0001558370-21-012840-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}